Search results for " immunologic"

showing 10 items of 538 documents

Antitumour activity of mononuclear phagocytes: role of tumour necrosis factor alpha.

1992

Tumour necrosis factor alpha (TNF) is a cytokine produced by mononuclear phagocytes (MP) originally discovered for its cytotoxic activity on tumour cell targets. It was subsequently demonstrated that, in addition to its oncolytic potential, TNF exerts a wide variety of activities on the host defensive system against malignancies. This article briefly reviews the current concepts on the role of TNF in the antitumour activity of MP.

Pulmonary and Respiratory MedicineCytotoxicity ImmunologicPhagocytesbusiness.industryTumor Necrosis Factor-alphamedicine.medical_treatmentCellTumour necrosis factor alphaOncolytic virusKiller Cells NaturalMajor Histocompatibility ComplexCytokinemedicine.anatomical_structureNeoplasmsImmunologymedicineCytotoxic T cellHumansTumor necrosis factor alphabusinessRespiration; international review of thoracic diseases
researchProduct

Allergological characterization of children treated with oral immunotherapy to egg

2018

Pulmonary and Respiratory MedicineOral immunotherapybusiness.industrymedicine.medical_treatmentImmunologyMEDLINEGeneral Medicinemedicine.diseaseAsthma03 medical and health sciences0302 clinical medicine030228 respiratory systemDesensitization ImmunologicChild PreschoolImmunologymedicineImmunology and AllergyHumans030212 general & internal medicinebusinessChildEgg HypersensitivityAsthmaDesensitization (medicine)
researchProduct

The role of the reporting framework MIATA within current efforts to advance immune monitoring

2014

Quality Controlmedicine.medical_specialtyLaboratory Proficiency TestingConsensusmedicine.medical_treatmentInternational CooperationT-LymphocytesImmunologyImmune monitoringPharmacologyImmunologic TestsImmune assaysMonitoring ImmunologicPredictive Value of TestsmedicineImmunology and AllergyHumansCooperative BehaviorIntensive care medicineImmune monitoringObserver Variationbusiness.industryGuideline adherenceMIATAImmunologic TestsReproducibility of ResultsImmunotherapyTreatment OutcomeReportingPredictive value of testsPractice Guidelines as TopicCooperative behaviorLaboratory Proficiency TestingGuideline AdherenceImmunotherapyCurrent (fluid)businessLaboratories
researchProduct

Sublingual immunotherapy: administration, dosages, use.

2009

Allergen extracts for sublingual immunotherapy (SLIT) are currently marketed by several manufacturers, with administration schedules and amount of allergen(s) quite variable in the different products, although almost all are standardized biologically or immunologically. The allergen extracts for SLIT are available in two main pharmaceutical forms: solution to be delivered by drop-counters, pre-dosed actuators (mini-pumps) or disposable single-dose vials; tablets with appropriate composition that allows a slow (1-2 minutes) dissolution in the mouth in contact with saliva. In Europe, SLIT is prescribed in general for one or a few allergens, and mixtures are less used, though there is no immun…

Randomized Controlled Trials as Topic; Humans; Allergens; Desensitization Immunologic; Vaccines; Administration SublingualDesensitization ImmunologicAllergenAdministration SublingualVaccineRandomized Controlled Trials as TopicHuman
researchProduct

The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264–272 Epitope

2002

Abstract Recently, we observed that CTL specific for the wild-type (wt) sequence p53264–272 peptide could only be expanded ex vivo from PBMC of a subset of the HLA-A2.1+ normal donors or cancer patients tested. Surprisingly, the tumors of the responsive patients expressed normal levels of wt p53 and could be considered unlikely to present this epitope. In contrast, tumors of nonresponsive patients accumulated mutant p53 and were more likely to present this epitope. We sought to increase the responsive rate to the wt p53264–272 peptide of PBMC obtained from normal donors and patients by identifying more immunogenic variants of this peptide. Two such variants were generated by amino acid exch…

Receptors Antigen T-Cell alpha-betaT cellImmunologyAntigen presentationEpitopes T-LymphocytePeptideBiologyLymphocyte ActivationEpitopeT-Lymphocyte SubsetsHLA-A2 AntigenImmune ToleranceTumor Cells CulturedmedicineHumansImmunology and AllergyGene Rearrangement beta-Chain T-Cell Antigen ReceptorCells CulturedMouth neoplasmchemistry.chemical_classificationAntigen PresentationT-cell receptorWild typeCytotoxicity Tests ImmunologicVirologyPeptide FragmentsCTL*medicine.anatomical_structureAmino Acid SubstitutionchemistryCarcinoma Squamous CellLeukocytes MononuclearMouth NeoplasmsTumor Suppressor Protein p53Protein BindingT-Lymphocytes CytotoxicThe Journal of Immunology
researchProduct

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pne…

2007

Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case-control studies were performed during the 2004-2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n=105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for p…

Relative risk reductionSqualeneAcute coronary syndromemedicine.medical_specialtyInfluenza vaccinePopulationPolysorbatesMass VaccinationAdjuvants ImmunologicRisk FactorsInternal medicinemedicineHumanseducationAgedAged 80 and overeducation.field_of_studyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryRespiratory diseasePublic Health Environmental and Occupational HealthOdds ratioPneumoniamedicine.diseaseVaccinationHospitalizationPneumoniaCerebrovascular DisordersInfectious DiseasesCardiovascular DiseasesInfluenza VaccinesSpainCase-Control StudiesImmunologyVaccines SubunitMolecular MedicinebusinessVaccine
researchProduct

The putative sponge aggregation receptor. Isolation and characterization of a molecule composed of scavenger receptor cysteine-rich domains and short…

1998

Porifera (sponges) are the oldest extant metazoan phylum. Dissociated sponge cells serve as a classic system to study processes of cell reaggregation. The reaggregation of dissociated cells is mediated by an extracellularly localized aggregation factor (AF), based on heterophilic interactions of the third order; the AF bridges two cells by ligating a cell-surface-bound aggregation receptor (AR). In the present study we report cloning, expression and immunohistochemical localization of a polypeptide from the marine sponge Geodia cydonium, which very likely represents the AR. The presumed AR gene gives rise to at least three forms of alternatively spliced transcripts of 6.5, 4.9 and 3.9 kb, a…

Repetitive Sequences Amino Acidmedicine.drug_classMolecular Sequence DataReceptors Cell SurfaceCell CommunicationMonoclonal antibodyPolymerase Chain Reactionlaw.inventionAntigenlawComplementary DNAConsensus SequencemedicineAnimalsAmino Acid SequenceCloning MolecularReceptors ImmunologicReceptorCell AggregationReceptors LipoproteinRepetitive Sequences Nucleic AcidReceptors ScavengerbiologyMolecular massBase SequenceSequence Homology Amino AcidMembrane ProteinsCell BiologySequence Analysis DNAScavenger Receptors Class BMolecular biologyRecombinant ProteinsPoriferaTransmembrane domainBiochemistrybiology.proteinRecombinant DNAAntibodyProtein Binding
researchProduct

Cancer and the microbiome : potential applications as new tumor biomarker

2015

Abstract: Microbial communities that colonize in humans are collectively described as microbiome. According to conservative estimates, about 15% of all types of neoplasms are related to different infective agents. However, current knowledge is not sufficient to explain how the microbiome contributes to the growth and development of cancers. Large and thorough studies involving colonized, diverse and complex microbiome entities are required to identify microbiome as a potential cancer marker and to understand how the immune system is involved in response to pathogens. This article reviews the existing evidence supporting the enigmatic association of transformed microbiome with the developmen…

RiskComputational biologyBiologycancer biomarkerImmune systemcancer diagnosisNeoplasmstransformed microbiomemedicineBiomarkers TumorAnimalsHumansPharmacology (medical)Microbiomecancer biomarker; cancer diagnosis; cancer prevention; immunological modification; transformed microbiome; Animals; Biomarkers; Tumor; Humans; Neoplasms; Risk; Microbiota; Oncology; Pharmacology (medical)Cancer markercancer diagnosiimmunological modificationCancer preventionTumorcancer preventionAnimalMicrobiotaCancermedicine.diseaseBiomarkercancer biomarker; cancer diagnosis; cancer prevention; immunological modification; transformed microbiome; Animals; Biomarkers Tumor; Humans; Neoplasms; Risk; Microbiota; Oncology; Pharmacology (medical)OncologyImmunologyNeoplasmHuman medicineBiomarkersHumanExpert review of anticancer therapy
researchProduct

Risk of scleroderma according to the type of immune checkpoint inhibitors

2020

Abstract Introduction Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). Among them, ICIs-induced systemic sclerosis (SSc) is poorly known. Methods To better characterize this irAE, our comprehensive approach combined the description of ICIs-induced scleroderma cases, the systematic review of the literature and the analysis of VigiBase, the WHO pharmacovigilance database. Results We identified two cases with underlying limited cutaneous SSc who presented a dramatic increase in the skin thickening following pembrolizumab, associated with scleroderma renal crisis in one case. In the literature, four cases of scleroderma and four cases of morphea hav…

Riskmedicine.medical_specialtyScleroderma SystemicDurvalumabintegumentary systembusiness.industryImmunologyScleroderma Renal CrisisIpilimumabPembrolizumabmedicine.diseaseDermatologySclerodermaAntineoplastic Agents ImmunologicalAtezolizumabNeoplasmsmedicineHumansImmunology and AllergyNivolumabskin and connective tissue diseasesbusinessMorpheamedicine.drugAutoimmunity Reviews
researchProduct

B subunits of cholera toxin and thermolabile enterotoxin of Escherichia coli have similar adjuvant effect as whole molecules on rotavirus 2/6-VLP spe…

2015

The purpose of this study was to evaluate the adjuvant effect of the B subunits of cholera toxin (CT) and the thermolabile enterotoxin of Escherichia coli (LT) by the intrarectal route of immunization and compare them to the whole molecules CT and LT-R192G, a non toxic mutant of LT, using 2/6-VLP as an antigen, in mice. All molecules induced similar antigen specific antibody titers in serum and feces, whereas different T cell profiles were observed. CTB and LTB, conversely to CT and LT-R192G, did not induce detectable production of IL-2 by antigen specific T cells. Moreover, CTB, conversely to LT-R192G, CT and LTB, did not induce antigen specific CD4+CD25+Foxp3- and Foxp3+ T cells, thus sho…

RotavirusCholera Toxin[SDV]Life Sciences [q-bio]T cellmedicine.medical_treatmentBacterial ToxinsEnterotoxinBiologymedicine.disease_causeAntibodies ViralMicrobiologyAntibodiesMicrobiologyB subunitEnterotoxinsFecesMiceAntigenAdjuvants ImmunologicImmunologicAdministration RectalmedicineAnimalsViralAdjuvantsIL-2 receptorVaccines Virus-Like ParticleThermolabileB cellVaccinesIntrarectalEscherichia coli ProteinsCholera toxinRotavirus VaccinesLT-R192G3. Good healthVirus-Like ParticleInfectious Diseasesmedicine.anatomical_structureAdministrationAntibody FormationInterleukin-2Th17 CellsImmunizationRectalAdjuvantImmunologic MemoryMicrobial pathogenesis
researchProduct